Unknown

Dataset Information

0

Novel Foot-and-Mouth Disease Vaccine Platform: Formulations for Safe and DIVA-Compatible FMD Vaccines With Improved Potency.


ABSTRACT: Inactivated, wild-type foot-and-mouth disease virus (FMDV) vaccines are currently used to control FMD around the world. These traditional FMD vaccines are produced using large quantities of infectious, virulent, wild-type FMD viruses, with the associated risk of virus escape from manufacturing facilities or incomplete inactivation during the vaccine formulation process. While higher quality vaccines produced from wild-type FMDV are processed to reduce non-structural antigens, there is still a risk that small amounts of non-structural proteins may be present in the final product. A novel, antigenically marked FMD-LL3B3D vaccine platform under development by Zoetis, Inc. and the USDA-ARS, consists of a highly attenuated virus platform containing negative antigenic markers in the conserved non-structural proteins 3Dpol and 3B that render resultant vaccines fully DIVA compatible. This vaccine platform allows for the easy exchange of capsid coding sequences to create serotype-specific vaccines. Here we demonstrate the efficacy of the inactivated FMD-LL3B3D-A24 Cruzeiro vaccine in cattle against wild-type challenge with A24 Cruzerio. A proprietary adjuvant system was used to formulate the vaccines that conferred effective protection at low doses while maintaining the DIVA compatibility. In contrast to wild-type FMDV, the recombinant FMD-LL3B3D mutant viruses have been shown to induce no clinical signs of FMD and no shedding of virus in cattle or pigs when inoculated as a live virus. The FMD-LL3B3D vaccine platform, currently undergoing development in the US, provides opportunities for safer vaccine production with full DIVA compatibility in support of global FMDV control and eradication initiatives.

SUBMITTER: Hardham JM 

PROVIDER: S-EPMC7544895 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel Foot-and-Mouth Disease Vaccine Platform: Formulations for Safe and DIVA-Compatible FMD Vaccines With Improved Potency.

Hardham John M JM   Krug Peter P   Pacheco Juan M JM   Thompson James J   Dominowski Paul P   Moulin Veronique V   Gay Cyril G CG   Rodriguez Luis L LL   Rieder Elizabeth E  

Frontiers in veterinary science 20200925


Inactivated, wild-type foot-and-mouth disease virus (FMDV) vaccines are currently used to control FMD around the world. These traditional FMD vaccines are produced using large quantities of infectious, virulent, wild-type FMD viruses, with the associated risk of virus escape from manufacturing facilities or incomplete inactivation during the vaccine formulation process. While higher quality vaccines produced from wild-type FMDV are processed to reduce non-structural antigens, there is still a ri  ...[more]

Similar Datasets

| S-EPMC5660475 | biostudies-literature
| S-EPMC3486329 | biostudies-literature
| S-EPMC6135822 | biostudies-literature
| S-EPMC8639872 | biostudies-literature
| S-EPMC7008245 | biostudies-literature
| S-EPMC9147724 | biostudies-literature
| S-EPMC6942242 | biostudies-literature
| S-EPMC8442236 | biostudies-literature
| S-EPMC9026347 | biostudies-literature
| S-EPMC9632437 | biostudies-literature